RO7234292 + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Huntingtons Disease
Conditions
Huntingtons Disease
Trial Timeline
Jan 23, 2019 → Mar 24, 2022
NCT ID
NCT03761849About RO7234292 + Placebo
RO7234292 + Placebo is a phase 3 stage product being developed by Roche for Huntingtons Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT03761849. Target conditions include Huntingtons Disease.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03761849 | Phase 3 | Completed |
Competing Products
1 competing product in Huntingtons Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| RO7234292 (RG6042) | Roche | Phase 1 | 33 |